EP3723761A4 - A solid oral dosage form comprising linagliptin - Google Patents

A solid oral dosage form comprising linagliptin Download PDF

Info

Publication number: EP3723761A4
Authority: EP; European Patent Office
Prior art keywords: linagliptin; dosage form; oral dosage; solid oral; solid
Prior art date: 2017-12-15
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

EP18914956.0A

Other languages

German (de)

French (fr)

Other versions

EP3723761A2 (en

Inventor

Ali TÜRKYILMAZ

Nur PEHLIVAN AKALIN

Merve ERGUN DONMEZ

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Sanovel Ilac Sanayi ve Ticaret AS

Original Assignee

Sanovel Ilac Sanayi ve Ticaret AS

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-12-15

Filing date

2018-12-14

Publication date

2021-06-30

2018-12-14 Application filed by Sanovel Ilac Sanayi ve Ticaret AS filed Critical Sanovel Ilac Sanayi ve Ticaret AS

2020-10-21 Publication of EP3723761A2 publication Critical patent/EP3723761A2/en

2021-06-30 Publication of EP3723761A4 publication Critical patent/EP3723761A4/en

Status Pending legal-status Critical Current

Links

LTXREWYXXSTFRX-QGZVFWFLSA-N Linagliptin Chemical compound N=1C=2N(C)C(=O)N(CC=3N=C4C=CC=CC4=C(C)N=3)C(=O)C=2N(CC#CC)C=1N1CCC[C@@H](N)C1 LTXREWYXXSTFRX-QGZVFWFLSA-N 0.000 title 1
229960002397 linagliptin Drugs 0.000 title 1
239000006186 oral dosage form Substances 0.000 title 1
239000007787 solid Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

EP18914956.0A 2017-12-15 2018-12-14 A solid oral dosage form comprising linagliptin Pending EP3723761A4 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
TR2017/20515A TR201720515A2 (en)	2017-12-15	2017-12-15	A SOLID ORAL DOSAGE FORM CONTAINING LINAGLIPTIN
PCT/TR2018/050812 WO2019203755A2 (en)	2017-12-15	2018-12-14	A solid oral dosage form comprising linagliptin

Publications (2)

Publication Number	Publication Date
EP3723761A2 EP3723761A2 (en)	2020-10-21
EP3723761A4 true EP3723761A4 (en)	2021-06-30

Family

ID=67900883

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP18914956.0A Pending EP3723761A4 (en)	2017-12-15	2018-12-14	A solid oral dosage form comprising linagliptin

Country Status (4)

Country	Link
EP (1)	EP3723761A4 (en)
CA (1)	CA3085455C (en)
TR (1)	TR201720515A2 (en)
WO (1)	WO2019203755A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2022173406A1 (en) *	2021-02-15	2022-08-18	Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi	A process for formulations of linagliptin or a pharmaceutically acceptable salt thereof
WO2024136773A1 (en) *	2022-12-21	2024-06-27	Santa Farma Ilac Sanayii A.S.	Stable pharmaceutical composition comprising linagliptin

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2010092124A1 (en) *	2009-02-13	2010-08-19	Boehringer Ingelheim International Gmbh	Pharmaceutical composition comprising linagliptin and optionally a sglt2 inhibitor, and uses thereof
US20140100236A1 (en) *	2012-10-09	2014-04-10	Boehringer Ingelheim International Gmbh	Use of selectively moisture-adjusted tabletting material in the production of mechanically stable tablets which contain at least one hydrate-forming active substance and/or adjuvant relevant to the mechanical stability of the tablets, particularly arginine-containing tablets
WO2014080383A1 (en) *	2012-11-26	2014-05-30	Ranbaxy Laboratories Limited	Pharmaceutical composition of dipeptidyl peptidase-iv (dpp-iv) inhibitors in combination with other antidiabetics

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2013128379A2 (en)	2012-02-27	2013-09-06	Dr. Reddy's Laboratories Limited	Crystalline polymorphic forms of linagliptin
WO2014080384A1 (en)	2012-11-26	2014-05-30	Ranbaxy Laboratories Limited	Pharmaceutical composition of linagliptin
CN106138059A (en) *	2015-03-27	2016-11-23	天津汉瑞药业有限公司	A kind of stable Li Gelieting pharmaceutical composition
EP3156048A1 (en) *	2015-10-13	2017-04-19	Galenicum Health S.L.	Stable pharmaceutical composition of linagliptin in the form of immediate release tablets

2017
- 2017-12-15 TR TR2017/20515A patent/TR201720515A2/en unknown
2018
- 2018-12-14 CA CA3085455A patent/CA3085455C/en active Active
- 2018-12-14 WO PCT/TR2018/050812 patent/WO2019203755A2/en unknown
- 2018-12-14 EP EP18914956.0A patent/EP3723761A4/en active Pending

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2010092124A1 (en) *	2009-02-13	2010-08-19	Boehringer Ingelheim International Gmbh	Pharmaceutical composition comprising linagliptin and optionally a sglt2 inhibitor, and uses thereof
US20140100236A1 (en) *	2012-10-09	2014-04-10	Boehringer Ingelheim International Gmbh	Use of selectively moisture-adjusted tabletting material in the production of mechanically stable tablets which contain at least one hydrate-forming active substance and/or adjuvant relevant to the mechanical stability of the tablets, particularly arginine-containing tablets
WO2014080383A1 (en) *	2012-11-26	2014-05-30	Ranbaxy Laboratories Limited	Pharmaceutical composition of dipeptidyl peptidase-iv (dpp-iv) inhibitors in combination with other antidiabetics

Also Published As

Publication number	Publication date
EP3723761A2 (en)	2020-10-21
CA3085455A1 (en)	2019-10-24
WO2019203755A3 (en)	2020-01-16
CA3085455C (en)	2022-08-16
WO2019203755A2 (en)	2019-10-24
TR201720515A2 (en)	2019-07-22

Legal Events

Date	Code	Title	Description
2019-10-25	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2020-09-18	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2020-09-18	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2020-10-21	17P	Request for examination filed	Effective date: 20200714
2020-10-21	AK	Designated contracting states	Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2020-10-21	AX	Request for extension of the european patent	Extension state: BA ME
2021-03-24	DAV	Request for validation of the european patent (deleted)
2021-03-24	DAX	Request for extension of the european patent (deleted)
2021-06-30	A4	Supplementary search report drawn up and despatched	Effective date: 20210601
2021-06-30	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 31/522 20060101AFI20210526BHEP Ipc: A61K 47/00 20060101ALI20210526BHEP Ipc: A61P 3/10 20060101ALI20210526BHEP
2023-02-03	TPAC	Observations filed by third parties	Free format text: ORIGINAL CODE: EPIDOSNTIPA
2023-08-16	P01	Opt-out of the competence of the unified patent court (upc) registered	Effective date: 20230708
2023-11-09	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2023-12-13	17Q	First examination report despatched	Effective date: 20231108

Publication	Publication Date	Title
GB2569961B (en)	2021-12-22	Pharmaceutical
GB2572126B (en)	2021-01-13	Pharmaceutical
GB201800073D0 (en)	2018-02-14	Pharmaceutical
EP3565502A4 (en)	2021-01-06	Oral irrigator
EP3437646A4 (en)	2019-11-27	Oral preparation having exceptional elutability
EP3603642A4 (en)	2020-09-02	Pharmaceutical preparation
EP3802562A4 (en)	2022-06-01	New pharmaceutical use
EP3402488A4 (en)	2019-08-14	Solid oral dosage forms of eslicarbazepine
EP3316848A4 (en)	2019-02-27	Oral devices
EP3590514A4 (en)	2021-01-06	Medicinal preparation
EP3281625A4 (en)	2018-08-29	Oral film preparation
IL271606A (en)	2020-02-27	Gastro-resistant controlled release oral dosage forms
EP3646866A4 (en)	2021-03-24	Pharmaceutical preparation
EP3727421A4 (en)	2021-07-28	Pharmaceutical compositions having a selected release duration
EP3723761A4 (en)	2021-06-30	A solid oral dosage form comprising linagliptin
EP3411024A4 (en)	2019-09-18	Loxapine film oral dosage form
EP3856177A4 (en)	2022-06-29	Grapiprant unit dosage forms
ZA202006346B (en)	2022-01-26	Pharmaceutical preparation
RS64906B1 (en)	2023-12-29	Pharmaceutical preparation
EP3697393A4 (en)	2021-10-13	Pharmaceutical dosage forms
GB201901989D0 (en)	2019-04-03	Pharmaceutical combinations
EP3718503A4 (en)	2021-07-28	Oral cleaner
EP3481379A4 (en)	2020-03-11	Oral dosage form containing a fast release exterior coating
GB2561723B (en)	2022-06-08	A composition for oral administration
EP3641734A4 (en)	2021-03-17	Abuse deterrent oral solid dosage form